Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
Yuliya Lytvyn(University Health Network), Jensen Yeung(Sunnybrook Health Science Centre), Muskaan Sachdeva(University of Toronto), Hiba Zaaroura(University of Toronto), Vimal H. Prajapati(University of Calgary), Asfandyar Mufti(University of Toronto), Ronald Vender(Dermatrials Research), Brian D. Rankin(University of Calgary), Justin D. Lu(Hamilton Health Sciences)
Cited by 4
Related Papers
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
|Circulation|2017|470
Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus
|American Journal of Physiology-Renal Physiology|2014|173
The New Biology of Diabetic Kidney Disease—Mechanisms and Therapeutic Implications
|Endocrine Reviews|2019|171
Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
|Diabetologia|2014|162
Uric Acid as a Biomarker and a Therapeutic Target in Diabetes
|Canadian Journal of Diabetes|2015|138